# CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

> **NCT07077083** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma (ccRCC)
- ccRCC

## Interventions

- **DRUG:** 89Zr-Girentuximab

## Key facts

- **NCT ID:** NCT07077083
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07077083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07077083, "CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07077083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*